Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at HC Wainwright

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by equities research analysts at HC Wainwright to a “strong-buy” rating in a research report issued on Friday,Zacks.com reports.

Several other analysts also recently issued reports on IKT. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Wednesday, October 8th. Cantor Fitzgerald upgraded Inhibikase Therapeutics to a “strong-buy” rating in a report on Thursday, December 11th. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a research note on Tuesday, December 2nd. Lifesci Capital upgraded Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, December 1st. Finally, Wall Street Zen raised Inhibikase Therapeutics to a “sell” rating in a research note on Saturday. Three analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy”.

Inhibikase Therapeutics Stock Performance

Shares of IKT opened at $2.00 on Friday. Inhibikase Therapeutics has a one year low of $1.33 and a one year high of $3.49. The stock has a 50-day moving average price of $1.56. The firm has a market capitalization of $150.36 million, a PE ratio of -5.13 and a beta of 0.88.

Inhibikase Therapeutics (NASDAQ:IKT) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.